RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07817082, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Histologically documented breast cancer:

    Inclusion criterion 4

    If local HER2 testing only classifies the subject's tumor as HER2-negative without available IHC status, the result must be re-confirmed by the Department of Pathology of Tianjin Medical University Cancer Institute and Hospital.

    Inclusion criterion 8

  3. History of myocardial infarction or symptomatic congestive heart failure (NYHA Class II-IV) within 6 months before enrollment. Subjects with troponin above ULN (per manufacturer reference range) without myocardial-infarction-related symptoms at screening shall receive cardiology consultation prior to enrollment to rule out myocardial infarction.

    Exclusion criterion 12

  4. For hormone-receptor-positive breast cancer: subjects have received 1-2 lines of endocrine therapy in the advanced-disease setting. Progression during adjuvant endocrine therapy or within 12 months after completion of adjuvant endocrine therapy counts as 1 prior line;

    Inclusion criterion 10

    For hormone-receptor-negative breast cancer: subjects have received 1-2 lines of prior systemic therapy. Progression during adjuvant therapy or within 12 months after completion of adjuvant therapy counts as 1 prior line;

    Inclusion criterion 11

    Female subjects of child-bearing potential must agree to use highly effective contraception from study screening through 7 months after the last dose of study drug and agree not to breast-feed. A negative serum pregnancy test must be obtained within 7 days prior to the first study drug administration;

    Inclusion criterion 22

    No radiotherapy, chemotherapy, molecular-targeted therapy, immunotherapy or surgery within 4 weeks prior to enrollment; toxicities from prior therapies have recovered to Grade ≤1 (wounds fully healed if surgery was performed). No endocrine therapy within 14 days prior to enrollment.

    Inclusion criterion 23

    HR-positive patients who have received systemic chemotherapy in the advanced-disease setting;<br/>Prior anti-HER2 therapy; prior or ongoing treatment with antibody-drug conjugates containing exatecan derivatives (topoisomerase I inhibitors), including DS-8201a, Sacituzumab govitecan (SG), etc.;

    Exclusion criterion 2

    Received local radiotherapy, endocrine therapy, or oral small-molecule targeted anti-tumor therapy within 14 days prior to first study drug administration;

    Exclusion criterion 4

    received anti-tumor immunotherapy, macromolecular anti-tumor agents, or chemotherapy within 28 days prior to first study drug administration OR five half-lives (whichever is shorter). For oral fluoropyrimidines, folinic acid agents and weekly paclitaxel chemotherapy, the wash-out period shall be ≥14 days; for nitrosoureas and mitomycin, the wash-out period shall be ≥42 days. Underwent major surgery (e.g., trans-abdominal, trans-thoracic surgery; excluding diagnostic puncture, infusion-device implantation, biliary stent implantation and other minor procedures) within 28 days prior to first study drug administration, or anticipated to require major surgery during the study period

    Exclusion criterion 5

    Stable brain metastasis: brain metastasis with no radiological progression (no new lesions, no enlargement of existing lesions) for at least 4 weeks after local therapy (stereotactic radiotherapy, whole-brain radiotherapy or surgery);

    Exclusion criterion 8

    Unresolved toxicity from prior anti-cancer therapy, defined as toxicity not recovered to ≤Grade 1 or baseline (alopecia excluded).

    Exclusion criterion 23

  5. ECOG performance status 0-1;

    Inclusion criterion 2

  6. . Hemoglobin ≥90 g/L (no blood transfusion within 14 days);

    Inclusion criterion 14

    . Absolute neutrophil count ≥1.5×10⁹/L;

    Inclusion criterion 15

    . Platelet count ≥90×10⁹/L;

    Inclusion criterion 16

    . Total bilirubin ≤1.5 × upper limit of normal (ULN);

    Inclusion criterion 17

    . Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; in the presence of liver metastases, ALT and AST ≤5 × ULN;

    Inclusion criterion 18

    . Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min (calculated by the Cockcroft-Gault formula);

    Inclusion criterion 19

    . International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN;

    Inclusion criterion 20

  7. Have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1;

    Inclusion criterion 12

  8. Other malignancies within the past 5 years, except for cured carcinoma in-situ of cervix, basal-cell carcinoma or squamous-cell carcinoma of skin (no treatment required for at least the past 3 years);

    Exclusion criterion 9

    Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, active hepatitis B (HBsAg-positive with HBV DNA ≥500 IU/mL), or active hepatitis C infection. Among subjects with positive hepatitis C antibody, only those with negative HCV RNA by PCR are eligible;

    Exclusion criterion 21

  9. Pregnant or lactating women; female subjects of child-bearing potential unwilling or unable to adopt effective contraceptive measures;

    Exclusion criterion 26

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07817082, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female subjects, aged ≥18 years and ≤75 years;
  • ECOG performance status 0-1;
  • Expected survival of no less than 3 months;
  • Histologically documented breast cancer:
  • Advanced or metastatic breast cancer
  • History of ultra-low HER2 expression: histopathology confirms ultra-low HER2 expression, defined as incomplete, faint membranous staining in ≤10% of invasive tumor cells.
  • If multiple historical/local HER2 test results are available for a subject, the most recent result derived from metastatic or advanced disease should be adopted.
  • If local HER2 testing only classifies the subject's tumor as HER2-negative without available IHC status, the result must be re-confirmed by the Department of Pathology of Tianjin Medical University Cancer Institute and Hospital.
  • Have radiographic or objective evidence of disease progression at or after the last prior systemic therapy before initiation of study treatment;
  • For hormone-receptor-positive breast cancer: subjects have received 1-2 lines of endocrine therapy in the advanced-disease setting. Progression during adjuvant endocrine therapy or within 12 months after completion of adjuvant endocrine therapy counts as 1 prior line;
  • For hormone-receptor-negative breast cancer: subjects have received 1-2 lines of prior systemic therapy. Progression during adjuvant therapy or within 12 months after completion of adjuvant therapy counts as 1 prior line;
  • Have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1;
  • Adequate major organ and bone marrow function meeting the following criteria:
  • . Hemoglobin ≥90 g/L (no blood transfusion within 14 days);
  • . Absolute neutrophil count ≥1.5×10⁹/L;
  • . Platelet count ≥90×10⁹/L;
  • . Total bilirubin ≤1.5 × upper limit of normal (ULN);
  • . Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; in the presence of liver metastases, ALT and AST ≤5 × ULN;
  • . Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min (calculated by the Cockcroft-Gault formula);
  • . International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN;
  • . Left ventricular ejection fraction (LVEF) ≥50%; QTc interval <470 ms for female subjects;
  • Female subjects of child-bearing potential must agree to use highly effective contraception from study screening through 7 months after the last dose of study drug and agree not to breast-feed. A negative serum pregnancy test must be obtained within 7 days prior to the first study drug administration;
  • No radiotherapy, chemotherapy, molecular-targeted therapy, immunotherapy or surgery within 4 weeks prior to enrollment; toxicities from prior therapies have recovered to Grade ≤1 (wounds fully healed if surgery was performed). No endocrine therapy within 14 days prior to enrollment.
  • Subjects voluntarily participate in the study and provide written informed consent, with anticipated good compliance to follow protocol-required study procedures.

Exclusion Criteria:

  • According to ASCO/CAP guidelines, subjects whose tumor has never been reported as HER2-positive (IHC 3+ or ISH-amplified);
  • HR-positive patients who have received systemic chemotherapy in the advanced-disease setting;<br/>Prior anti-HER2 therapy; prior or ongoing treatment with antibody-drug conjugates containing exatecan derivatives (topoisomerase I inhibitors), including DS-8201a, Sacituzumab govitecan (SG), etc.;
  • Known history of severe hypersensitivity to the drug substance, inactive ingredients in the pharmaceutical formulation, or other monoclonal antibodies;
  • Received local radiotherapy, endocrine therapy, or oral small-molecule targeted anti-tumor therapy within 14 days prior to first study drug administration;
  • received anti-tumor immunotherapy, macromolecular anti-tumor agents, or chemotherapy within 28 days prior to first study drug administration OR five half-lives (whichever is shorter). For oral fluoropyrimidines, folinic acid agents and weekly paclitaxel chemotherapy, the wash-out period shall be ≥14 days; for nitrosoureas and mitomycin, the wash-out period shall be ≥42 days. Underwent major surgery (e.g., trans-abdominal, trans-thoracic surgery; excluding diagnostic puncture, infusion-device implantation, biliary stent implantation and other minor procedures) within 28 days prior to first study drug administration, or anticipated to require major surgery during the study period
  • Meningeal metastasis or active parenchymal brain metastasis. Subjects with clinically stable parenchymal brain metastasis may be enrolled, including asymptomatic brain metastases without prior local therapy; or subjects with previously treated CNS metastases (radiotherapy or surgery), provided radiological stability has been maintained for at least 4 weeks AND symptomatic treatment (including corticosteroids, mannitol, etc.) has been discontinued for more than 2 weeks.
  • Active brain metastasis: newly-diagnosed brain lesions without local therapy (surgery or radiotherapy), or radiologically progressive brain metastasis after prior treatment.
  • Stable brain metastasis: brain metastasis with no radiological progression (no new lesions, no enlargement of existing lesions) for at least 4 weeks after local therapy (stereotactic radiotherapy, whole-brain radiotherapy or surgery);
  • Other malignancies within the past 5 years, except for cured carcinoma in-situ of cervix, basal-cell carcinoma or squamous-cell carcinoma of skin (no treatment required for at least the past 3 years);
  • Uncontrolled concurrent diseases, including but not limited to: persistent or active infection, uncontrolled or significant cardiovascular disease, severe chronic gastrointestinal disease accompanied by diarrhea, or psychiatric/social conditions that may compromise protocol compliance, substantially increase adverse-event risk, or impair the subject's ability to provide written informed consent;
  • Uncontrolled or significant cardiovascular disease, defined by any of the following:
  • History of myocardial infarction or symptomatic congestive heart failure (NYHA Class II-IV) within 6 months before enrollment. Subjects with troponin above ULN (per manufacturer reference range) without myocardial-infarction-related symptoms at screening shall receive cardiology consultation prior to enrollment to rule out myocardial infarction.
  • Uncontrolled hypertension;
  • Uncontrolled and/or clinically significant arrhythmia;
  • Mean QTcF interval (QT corrected by Fredericia formula) >470 ms for female subjects, derived from three screening 12-lead ECGs;
  • History of non-infectious interstitial lung disease (ILD)/non-infectious pneumonitis requiring steroid therapy; current ILD / non-infectious pneumonitis; or suspected ILD / non-infectious pneumonitis that cannot be excluded by imaging at screening;
  • Clinically significant pulmonary comorbidities, including but not limited to underlying pulmonary diseases (i.e., pulmonary embolism within 3 months prior to screening, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, significant pleural effusion, etc.), autoimmune / connective-tissue / inflammatory diseases with pulmonary involvement (i.e., rheumatoid arthritis, Sjögren syndrome, sarcoidosis, etc.), and/or prior complete pulmonary resection;
  • Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes within 2 weeks before first study drug administration (dose >10 mg/day prednisone or equivalent physiological dose of other corticosteroids); nasal or inhaled corticosteroids are excluded;
  • Active autoimmune disease, or history of autoimmune disease prone to relapse. Subjects with skin disorders not requiring systemic therapy (e.g., vitiligo, psoriasis, alopecia), well-controlled type 1 diabetes treated with insulin, or childhood-onset asthma fully resolved without adult-period intervention are eligible. Subjects requiring bronchodilator medical intervention for asthma are excluded;
  • Uncontrolled infection requiring intravenous antibiotics, antiviral or antifungal agents;
  • Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, active hepatitis B (HBsAg-positive with HBV DNA ≥500 IU/mL), or active hepatitis C infection. Among subjects with positive hepatitis C antibody, only those with negative HCV RNA by PCR are eligible;
  • Received live-attenuated vaccine within 30 days prior to first study-drug administration (mRNA vaccines and non-replicating adenoviral vaccines are not regarded as live-attenuated vaccines). Note: If enrolled, subjects shall not receive live vaccines during the study and within 30 days after last study-drug dose;
  • Unresolved toxicity from prior anti-cancer therapy, defined as toxicity not recovered to ≤Grade 1 or baseline (alopecia excluded).

Note: Subjects with chronic stable Grade 2 toxicity judged by investigator to be related to prior anti-cancer therapy (defined as no deterioration to ≥Grade 2 for at least 3 months before enrollment and manageable with standard care) may be enrolled, e.g., chemotherapy-induced neuropathy, fatigue. Residual toxicities from prior immuno-oncology therapy including Grade 1 or 2 endocrine disorders are allowed: (a) hypothyroidism / hyperthyroidism; (b) type 1 diabetes mellitus; (c) hyperglycemia; (d) adrenal insufficiency; (e) adrenalitis; (f) skin depigmentation (vitiligo);

  • Imaging demonstrates tumor encasement of major blood vessels, or investigator-judged high risk of tumor invasion into major blood vessels leading to life-threatening hemorrhage during treatment;
  • Non-healing wounds or fractures for prolonged periods; major surgical procedures or severe traumatic injury, fracture or ulcer within 4 weeks prior to enrollment;
  • Pregnant or lactating women; female subjects of child-bearing potential unwilling or unable to adopt effective contraceptive measures;
  • Any other conditions judged by the investigator that may interfere with study conduct or endpoint assessment.

Quoted from ClinicalTrials.gov, NCT07817082, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07817082, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07817082